TME Pharma NV
ALTME
Company Profile
Business description
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
Contact
Max-Dohrn-Street 8-10
Berlin10589
DEUT: +49 30166370820
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,994.70 | 20.70 | -0.23% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 24,879.66 | 297.27 | -1.18% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 40,960.45 | 305.75 | 0.75% |
| NZX 50 Index | 12,830.37 | 25.60 | -0.20% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,738.30 | 18.10 | -0.21% |
| SSE Composite Index | 3,591.26 | 24.46 | -0.68% |